WO2025202714 - METHODS FOR TREATING PRIMARY SJOGREN'S SYNDROME USING FCRN ANTAGONISTS
National phase entry is expected:
Publication Number
WO/2025/202714
Publication Date
02.10.2025
International Application No.
PCT/IB2025/000125
International Filing Date
26.03.2025
Title **
[English]
METHODS FOR TREATING PRIMARY SJOGREN'S SYNDROME USING FCRN ANTAGONISTS
[French]
MÉTHODES DE TRAITEMENT DU SYNDROME DE SJÖGREN PRIMAIRE À L'AIDE D'ANTAGONISTES DE FCRN
Applicants **
ARGENX BV
Inventors
VAN MIDDENDORP, Joost Johannes
PAPADOPOULOU, Despoina
JACOBS, Julie
MEYVISCH, Paul
PEENE, Isabelle
ELEWAUT, Dirk
ROHANE, Patricia
BOWEN, Edward
Priority Data
63/569,943
26.03.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3660 | |
| EPO | Filing, Examination, Granting | 26588 | |
| Japan | Filing, Examination, Granting | 3104 | |
| South Korea | Filing, Examination, Granting | 3903 | |
| USA | Filing, Examination, Granting | 10790 |
Total:
48,045
Contact Us
Abstract[English]
Provided herein are methods of treating primary Sjögren's syndrome (pSS) using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of pSS and for use in the manufacture of a medicament for the treatment of pSS are also provided herein.[French]
L'invention concerne des méthodes de traitement du syndrome de Sjögren primaire (pSS) à l'aide d'une quantité efficace d'un antagoniste du récepteur Fc néonatal (FcRn) humain. L'invention concerne également des antagonistes de FcRn destinés à être utilisés dans le traitement de pSS et destinés à être utilisés dans la fabrication d'un médicament pour le traitement de pSS.